Journal Mobile Options
Table of Contents
Vol. 67, No. 2, 2004
Issue release date: September 2004
Oncology 2004;67:166–173

Thrombin Inhibitor, Argatroban, Prevents Tumor Cell Migration and Bone Metastasis

Asanuma K. · Wakabayashi H. · Hayashi T. · Okuyama N. · Seto M. · Matsumine A. · Kusuzaki K. · Suzuki K. · Uchida A.
Departments of aOrthopedic Surgery and bMolecular Pathobiology, Mie University School of Medicine, TsuCity, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


It is well known that malignant cells show procoagulant activity, which is associated with their metastatic potential. Thrombin, the key enzyme of the blood coagulation system, is generated around tumor cells, promoting the migration and metastasis of tumor cells. In this study, we evaluated the effect of argatroban, a specific thrombin inhibitor, on the migration and metastasis of B16BL6 melanoma cells. In vitro argatroban dose-dependently inhibited cell migration, the maximum inhibition being observed in the presence of 10 µM argatroban (p < 0.0001). In order to investigate the antimetastatic effect of the thrombin inhibitor, we used an animal model that we have reported previously. C57BL6 mice which had received a bone (femur or tibia) transplanted into the dorsal subcutis were injected with B16 melanoma cells into the left heart ventricle. Intraperitoneal injection of argatroban (9 mg/kg/day for 4 weeks) significantly reduced the number of limbs with metastatic lesions as compared to a placebo (p < 0.05). These results suggest that argatroban was associated with reduced melanoma metastases by inhibiting cell migration. Our results showed that argatroban is effective for treatment of bone metastasis.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Magennis DP, Orchard GE: Malignant melanoma: Death by image and ignorance, diagnosis by surgical excision and laboratory investigation. Br J Biomed Sci 1999;56:134–144.
  2. Lorigan JG, Wallace S, Mavligit GM: The prevalence and location of metastases from ocular melanoma: Imaging study in 110 patients. AJR Am J Roentgenol 1991;157:1279–1281.
  3. Mundy GR: Mechanisms of bone metastasis. Cancer 1997;80:1546–1556.
  4. Yoneda T: Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone. Eur J Cancer 1998;34:240–245.
  5. Hiraga T, Tanaka S, Yamamoto M, Nakajima T, Ozawa H: Inhibitory effects of bisphosphonate (YM175) on bone resorption induced by a metastatic bone tumor. Bone 1996;18:1–7.
  6. Sakai T, Kisiel W: Binding of human factors X and Xa to HepG2 and J82 human tumor cell lines. Evidence that factor Xa binds to tumor cells independent of factor Va. J Biol Chem 1990;265:9105–9113.
  7. Rickles FR, Edwards RL: Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood 1983;62:14–31.
  8. Murray JC: Coagulation and cancer. Br J Cancer 1991;64:422–424.
  9. Rao LV: Tissue factor as a tumor procoagulant. Cancer Metastasis Rev 1992;11:249–266.
  10. Gordon SG: Cancer cell procoagulants and their role in malignant disease. Semin Thromb Hemost 1992;18:424–433.
  11. Costantini V, Zacharski LR: Fibrin and cancer. Thromb Haemost 1993;69:406–414.
  12. Kaplan KL, Francis CW: Direct thrombin inhibitors. Semin Hematol 2002;39:187–196.
  13. Zain J, Huang YQ, Feng X, Nierodzik ML, Li JJ, Karpatkin S: Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells. Blood 2000;95:3133–3138.
  14. Amirkhosravi A, Meyer T, Chang JY, Amaya M, Siddiqui F, Desai H, Francis JL: Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost 2002;87:930–936.
  15. Suzuki K, Nishioka J, Hayashi T: Localization of thrombomodulin-binding site within human thrombin. J Biol Chem 1990;265:13263–13267.
  16. Bernatowicz MS, Klimas CE, Hartl KS, Peluso M, Allegretto NJ, Seiler SM: Development of potent thrombin receptor antagonist peptides. J Med Chem 1996;39:4879–4887.
  17. Albrecht-Buehler G: The phagokinetic tracks of 3T3 cells. Cell 1977;11:395–404.
  18. Zhou H, Gabazza EC, Takeya H, Deguchi H, Urano H, Adachi Y, Suzuki K: Prothrombin and its derivatives stimulate motility of melanoma cells. Thromb Haemost 1998;80:407–412.
  19. Wakabayashi H, Hibasami H, Iida K, Satoh N, Yamazaki T, Sonoda J, Hirata H, Nakashima K, Uchida A: Prevention of metastasis by a polyamine synthesis inhibitor in an animal bone metastasis model. Oncology 2000;59:75–80.
  20. Wojtukiewicz MZ, Sierko E, Zacharski LR, Zimnoch L, Kudryk B, Kisiel W: Tissue factor-dependent coagulation activation and impaired fibrinolysis in situ in gastric cancer. Semin Thromb Hemost 2003;29:291–300.
  21. Rickles FR, Shoji M, Abe K: The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: Tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer. Int J Hematol 2001;73:145–150.
  22. Seto S, Onodera H, Kaido T, Yoshikawa A, Ishigami S, Arii S, Imamura M: Tissue factor expression in human colorectal carcinoma: Correlation with hepatic metastasis and impact on prognosis. Cancer 2000;88:295–301.
  23. Poon RT, Lau CP, Ho JW, Yu WC, Fan ST, Wong J: Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res 2003;9:5339–5345.
  24. Forster Y, Meye A, Albrecht S, Kotzsch M, Fussel S, Wirth MP, Schwenzer B: Tissue specific expression and serum levels of human tissue factor in patients with urological cancer. Cancer Lett 2003;193:65–73.
  25. Chen LB, Buchanan JM: Mitogenic activity of blood components. I. Thrombin and prothrombin. Proc Natl Acad Sci USA 1975;72:131–135.
  26. Carney DH, Glenn KC, Cunningham DD: Conditions which affect initiation of animal cell division by trypsin and thrombin. J Cell Physiol 1978;95:13–22.
  27. Glenn KC, Carney DH, Fenton JW 2nd, Cunningham DD: Thrombin active site regions required for fibroblast receptor binding and initiation of cell division. J Biol Chem 1980;255:6609–6616.
  28. Carney DH, Stiernberg J, Fenton JW 2nd: Initiation of proliferative events by human alpha-thrombin requires both receptor binding and enzymic activity. J Cell Biochem 1984;26:181–195.
  29. Morris DL, Ward JB Jr, Nechay P, Whorton EB Jr, Fenton JW 2nd, Carney DH: Highly purified human alpha-thrombin promotes morphological transformation of BALB/c 3T3 cells. Carcinogenesis 1992;13:1–7.
  30. McNamara CA, Sarembock IJ, Gimple LW, Fenton JW 2nd, Coughlin SR, Owens GK: Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest 1993;91:94–98.
  31. Nierodzik ML, Kajumo F, Karpatkin S: Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. Cancer Res 1992;52:3267–3272.
  32. Nierodzik ML, Plotkin A, Kajumo F, Karpatkin S: Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. J Clin Invest 1991;87:229–236.
  33. Klepfish A, Greco MA, Karpatkin S: Thrombin stimulates melanoma tumor-cell binding to endothelial cells and subendothelial matrix. Int J Cancer 1993;53:978–982.
  34. Yamamoto N, Greco NJ, Barnard MR, Tanoue K, Yamazaki H, Jamieson GA, Michelson AD: Glycoprotein Ib (GPIb)-dependent and GPIb-independent pathways of thrombin-induced platelet activation. Blood 1991;77:1740–1748.
  35. Gralnick HR, Williams S, McKeown LP, Hansmann K, Fenton JW 2nd, Krutzsch H: High-affinity alpha-thrombin binding to platelet glycoprotein Ib alpha: Identification of two binding domains. Proc Natl Acad Sci USA 1994;91:6334–6338.
  36. Rasmussen UB, Vouret-Craviari V, Jallat S, Schlesinger Y, Pages G, Pavirani A, Lecocq JP, Pouyssegur J, Van Obberghen-Schilling E: cDNA cloning and expression of a hamster alpha-thrombin receptor coupled to Ca2+ mobilization. FEBS Lett 1991;288:123–128.
  37. Ishihara H, Connolly AJ, Zeng D, Kahn ML, Zheng YW, Timmons C, Tram T, Coughlin SR: Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997;386:502–506.
  38. Wojtukiewicz MZ, Tang DG, Nelson KK, Walz DA, Diglio CA, Honn KV: Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta 3 expression on the cell surface. Thromb Res 1992;68:233–245.
  39. Esumi N, Fan D, Fidler IJ: Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. Cancer Res 1991;51:4549–4556.
  40. Perez M, Migliaccio S, Taranta A, Festuccia C, Orru L, Brama M, Bologna M, Faraggiana T, Baron R, Teti A: Melanoma cells stimulate osteoclastogenesis, c-Src expression and osteoblast cytokines. Eur J Cancer 2001;37:629–640.
  41. Abraham LA, Jenkins AL, Stone SR, Mackie EJ: Expression of the thrombin receptor in developing bone and associated tissues. J Bone Miner Res 1998;13:818–827.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50